A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.

@article{Lai2011ASG,
  title={A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.},
  author={Chien-Han Lai and Yuan-Yu Hsu},
  journal={The international journal of neuropsychopharmacology},
  year={2011},
  volume={14 2},
  pages={
          225-35
        }
}
  • Chien-Han Lai, Y. Hsu
  • Published 1 March 2011
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
We designed this study to investigate the modulating effects of duloxetine on symptoms and grey matter of patients with major depressive disorder combined with panic disorder. We also aimed to discover if there was any persistence of grey-matter deficits after remission and to find 'trait markers' for this comorbidity. High-resolution magnetic resonance imaging and voxel-based morphometric measurements were performed on 15 patients at baseline and remitted status (week 6) compared to 15 healthy… 
Changes in gray matter volume of remitted first-episode, drug-naïve, panic disorder patients after 6-week antidepressant therapy.
Changes in regional homogeneity of parieto-temporal regions in panic disorder patients who achieved remission with antidepressant treatment.
The gray matter alterations in major depressive disorder and panic disorder: Putative differences in the pathogenesis.
Structural MRI correlates for vulnerability and resilience to major depressive disorder.
TLDR
The HC-FHP group had smaller hippocampal volumes compared with patients with MDD, which is suggestive for neuroplastic effects of treatment, and resilience is associated with the larger white matter volumes in the DMPFC.
Gray matter increases in fronto-parietal regions of depression patients with aripiprazole monotherapy
TLDR
The changes in the GMV of fronto-parieto-temporal regions and residual GMV deficits in the superior frontal gyrus might represent “state-dependent brain changes” and “residual-deficit brain regions,” respectively, for aripiprzole monotherapy in MDD.
Reduced Gray Matter Density in the Posterior Cerebellum of Patients with Panic Disorder : A Voxel-Based Morphometry Study
TLDR
The findings suggest that the gray matter deficits in the posterior cerebellum may be involved in the pathogenesis of panic disorder.
State-dependent changes in hippocampal grey matter in depression
TLDR
An increase in grey matter was observed in the hippocampus following treatment with citalopram in currently depressed patients, and this is a potential biomarker for a depressive episode.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels
TLDR
The present data seem to suggest an optimal anxiolytic efficacy of DLX at intermediate plasma levels, which may be helpful in predicting better treatment responses and tolerability.
Depression-related variation in brain morphology over 3 years: effects of stress?
TLDR
Findings from animal studies of neuroplastic stress-related processes that occur in the hippocampus, amygdala, dorsomedial prefrontal cortex, dorsolateral cortex, and anterior cingulum during depressive episodes are supported.
Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression.
TLDR
The authors observed larger OFC regional volumes in depressed patients exposed to antidepressants compared to the drug-naive depressed subjects, but smaller than those in age-matched controls, suggesting that antidepressants may protect against gray matter loss in geriatric depression.
Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study.
TLDR
The results suggest that a relatively small hippocampal volume may be a vulnerability factor for a bad treatment response in major depression.
Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response
...
1
2
3
4
5
...